Daniel J Landsburg, MD
Associate Professor of Clinical Medicine (Hematology-Oncology)
Medical Director, Infusion Services, Hospital of the University of Pennsylvania
Faculty Leader, Hematology/Oncology Fellowship Quality Improvement and Patient Safety Education, Hospital of the University of Pennsylvania
Faculty mentor, Department of Medicine Healthcare Leadership in Quality Residency Track, Hospital of the University of Pennsylvania
Physician Leader, Oncology Clinical Effectiveness Team, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-7361
Fax: 215-615-5888
Fax: 215-615-5888
Education:
BA
University of Pennsylvania, 2004.
MD
Temple University School of Medicine, 2008.
Permanent linkBA
University of Pennsylvania, 2004.
MD
Temple University School of Medicine, 2008.
Description of Clinical Expertise
B cell lymphomaHodgkin lymphoma
Autologous stem cell transplantation
CART-19 therapy
Description of Other Expertise
Clinical operationsQuality improvement
Patient safety
Description of Research Expertise
Therapy for large B cell lymphomaMolecular classification of large B cell lymphoma
CART-19 therapy
Selected Publications
Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ.: Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer 13(2): e009890, Feb 2025.Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ.: Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease. Clin Lymphoma Myeloma Leuk 25(1): 45-51, Jan 2025 Notes: DOI: 10.1016/j.clml.2024.08.010
Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ.: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther 00912-1.(25): S2666-6367, Jan 2025 Notes: DOI: 10.1016/j.jtct.2025.01.884
Landsburg, DJ: Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing. Cancers (Basel) 17(1): 18, Dec 2024.
Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF.: Genomic features of newly diagnosed large B cell lymphoma with or without subsequent disease progression. Cancer Res Commun 4(11): 2947-2954, Oct 2024.
Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ.: Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP. Haematologica 110: doi: 10.3324/haematol.2024.286560. Nov 2024 Notes: Online ahead of print.
Schneider, Michael, Landsburg, Daniel: The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review. Annals of Lymphoma 8: doi: 10.21037/aol-23-19, Mar 2024.
Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A.: TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era. Blood Adv 7(23): 7243-7253, Oct 2023.
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplant Cell Ther 29(8): 495-503. Aug 2023.
Landsburg DJ, Nasta SD, Gerson JN, Svoboda J, Chong EA, Schuster SJ, Barta SK, Robinson KW, Hughes ME.: Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy. Leuk Lymphoma 63(1): 243-246. Jan 2022.
Landsburg DJ, Morrissette JJD, Schuster SJ, Nasta SD, Gerson JN, Barta SK, Svoboda J, Chong EA, Lim MS.: Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. Oncotarget 13: 1237-1244, Nov 2022.